Payment overview · 2025
General Payments
$1,322.80
61 reported records · 19 companies
Healthcare provider profile · identity verified
Carlos E Munoz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RICHMOND, TX · NPI 1043269285
Verified facts
What the public records show
CMS Open Payments records show Carlos E Munoz, M.D. received $1,322.80 in general payments during 2025 across 61 reported records.
Novo Nordisk Inc accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Prolia, Rexulti, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 334 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $172.99 | 13.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $167.17 | 12.6% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.02 | 11.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.30 | 8.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.54 | 7.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.67 | 7.3% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.40 | 5.6% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.53 | 5.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.85 | 3.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.73 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.83 | 3.3% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $43.30 | 3.3% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $37.69 | 2.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.91 | 2.6% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.31 | 2.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.10 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.97 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.93 | 1.6% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $18.56 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,322.80 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $148.56 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.05 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.32 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.54 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.67 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.01 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.01 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.95 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.67 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.83 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $43.30 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $43.30 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.94 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.10 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 196 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 127 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 182 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 334 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 18 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 68 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 64 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
182 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
334 | 72 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 855 | 323 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 817 | 279 |
| Levothyroxine Sodium | Levothyroxine Sodium | 804 | 248 |
| Lisinopril | Lisinopril | 631 | 227 |
| Metformin Hcl | Metformin Hcl | 603 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 222 |
| Gabapentin | Gabapentin | 439 | 191 |
| Pantoprazole Sodium | Pantoprazole Sodium | 400 | 157 |
| Losartan Potassium | Losartan Potassium | 363 | 121 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 343 | 144 |
| Ozempic | Semaglutide | 334 | 72 |
| Furosemide | Furosemide | 266 | 125 |
| Carvedilol | Carvedilol | 259 | 108 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 106 |
| Fluticasone Propionate | Fluticasone Propionate | 239 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 227 | 92 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 211 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 78 |
| Omeprazole | Omeprazole | 207 | 88 |
| Tramadol Hcl | Tramadol Hcl | 205 | 56 |
| Glimepiride | Glimepiride | 199 | 62 |
| Azithromycin | Azithromycin | 198 | 145 |
| Trazodone Hcl | Trazodone Hcl | 198 | 106 |
| Eliquis | Apixaban | 196 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 72 |
| Potassium Chloride | Potassium Chloride | 188 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 186 | 70 |
| Simvastatin | Simvastatin | 185 | 62 |
| Doxycycline Hyclate | Doxycycline Hyclate | 182 | 145 |
| Mounjaro | Tirzepatide | 182 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 175 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 58 |
| Celecoxib | Celecoxib | 147 | 51 |
| Mirtazapine | Mirtazapine | 139 | 69 |
| Alprazolam | Alprazolam | 129 | 35 |
| Prednisone | Prednisone | 129 | 82 |
| Farxiga | Dapagliflozin Propanediol | 127 | 34 |
| Montelukast Sodium | Montelukast Sodium | 127 | 60 |
| Methylprednisolone | Methylprednisolone | 120 | 100 |
| Clonazepam | Clonazepam | 116 | 32 |
| Cefdinir | Cefdinir | 115 | 97 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 111 | 89 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 109 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 33 |
| Meclizine Hcl | Meclizine Hcl | 107 | 59 |
| Glipizide | Glipizide | 104 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 30 |
| Nifedipine Er | Nifedipine | 104 | 43 |
| Jardiance | Empagliflozin | 99 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 33 |
| Sertraline Hcl | Sertraline Hcl | 98 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 58 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 94 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 67 |
| Alendronate Sodium | Alendronate Sodium | 92 | 31 |
| Fenofibrate | Fenofibrate | 92 | 33 |
| Ezetimibe | Ezetimibe | 90 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 32 |
| Meloxicam | Meloxicam | 89 | 42 |
| Donepezil Hcl | Donepezil Hcl | 87 | 37 |
| Metformin Hcl Er | Metformin Hcl | 85 | 38 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 84 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 27 |
| Famotidine | Famotidine | 77 | 36 |
| Finasteride | Finasteride | 77 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 24 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 75 | 19 |
| Allopurinol | Allopurinol | 74 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 26 |
| Memantine Hcl | Memantine Hcl | 71 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 32 |
| Rybelsus | Semaglutide | 68 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 65 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 64 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 22 |
| Synthroid | Levothyroxine Sodium | 64 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 51 |
| Promethazine Hcl | Promethazine Hcl | 58 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 20 |
| Lorazepam | Lorazepam | 52 | 17 |
| Lovastatin | Lovastatin | 52 | 13 |
| Mupirocin | Mupirocin | 52 | 36 |
| Ramipril | Ramipril | 52 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 23 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 50 | 16 |
| Enalapril Maleate | Enalapril Maleate | 50 | 18 |
| Pregabalin | Pregabalin | 49 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 48 | 12 |
| Colchicine | Colchicine | 48 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | 14 |
| Xarelto | Rivaroxaban | 47 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | 23 |
| Nitroglycerin | Nitroglycerin | 46 | 18 |
| Fluconazole | Fluconazole | 45 | 21 |
| Ketoconazole | Ketoconazole | 45 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 26 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 24 |
| Glipizide Er | Glipizide | 41 | 12 |
| Levofloxacin | Levofloxacin | 40 | 32 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 13 |
| Atenolol | Atenolol | 38 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | 11 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 14 |
| Risperidone | Risperidone | 36 | 26 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 13 |
| Metronidazole | Metronidazole | 35 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Naproxen | Naproxen | 34 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 33 | 13 |
| Azelastine Hcl | Azelastine Hcl | 32 | 21 |
| Nystatin | Nystatin | 32 | 17 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 32 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 15 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 13 |
| Clonidine Hcl | Clonidine Hcl | 29 | 15 |
| Metolazone | Metolazone | 29 | 17 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 13 |
| Baclofen | Baclofen | 26 | 19 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | 11 |
| Valsartan | Valsartan | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 18 |
| Aripiprazole | Aripiprazole | 18 | 13 |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 17 |
| Prolia | Denosumab | 18 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,322.80 · 61 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Flector, Flexitouch Plus, GEMTESA, JARDIANCE, Kerendia, Licart, MOUNJARO, NURTEC ODT, NUZYRA, Nimbl, OTEZLA, Ozempic, PANCREAZE, PROLIA, REPATHA, REXULTI, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tirosint, UBRELVY, Wegovy, ZENPEP, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error